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Abstract
In this study, we have demonstrated that Korean Panax ginseng (KG) significantly enhances myelopoiesis in vitro and
reconstitutes bone marrow after 5-flurouracil-induced (5FU) myelosuppression in mice. KG promoted total white blood cell,
lymphocyte, neutrophil and platelet counts and improved body weight, spleen weight, and thymus weight. The number of
CFU-GM in bone marrow cells of mice and serum levels of IL-3 and GM-CSF were significantly improved after KG treatment.
KG induced significant c-Kit, SCF and IL-1 mRNA expression in spleen. Moreover, treatment with KG led to marked
improvements in 5FU-induced histopathological changes in bone marrow and spleen, and partial suppression of thymus
damage. The levels of IL-3 and GM-CSF in cultured bone marrow cells after 24 h stimulation with KG were considerably
increased. The mechanism underlying promotion of myelopoiesis by KG was assessed by monitoring gene expression at
two time-points of 4 and 8 h. Treatment with Rg1 (0.5, 1 and 1.5 mmol) specifically enhanced c-Kit, IL-6 and TNF-a mRNA
expression in cultured bone marrow cells. Our results collectively suggest that the anti-myelotoxicity activity and promotion
of myelopoiesis by KG are mediated through cytokines. Moreover, the ginsenoside, Rg1, supports the role of KG in
myelopoiesis to some extent.
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Introduction
Blood/bone marrow system one of the largest organs in the
body, is an important potential target of chemical exposure, in
particular, chemotherapeutic agents and ionizing radiation.
Consequently, analysis of blood and bone marrow has become a
routine procedure in the investigation of hematological and bone
marrow disorders in chemotherapy and radiotherapy assessments
[1,2]. 5-Fluorouracil (5FU), a pyrimidine analog, is an active
chemotherapy drug that is widely used to treat a variety of tumors,
including colorectal, breast, and liver carcinomas [3]. However,
myelosuppression after 5FU application is a major limiting factor
in the clinical treatment of cancers. Toxicity has profound
consequences on patients, affecting not only their therapeutic
options but also overall quality of life, and restricts the extensive
clinical application of 5FU. Notably, 5FU-induced side-effects
often lead to discontinuation of treatment [4]. An earlier study
showed that ,40–47% of patients receiving protracted venous
infusion of 5FU (300 mg/m
2/day) for two years required delay in
treatment and/or dose reduction due to fatigue and a decrease in
the number of blood and bone marrow cells [5].
Ginseng, the root of Panax ginseng C.A. Meyer, is traditionally
used as a restorative, anti-diabetic, anti-vomiting, and anti-cancer
agent worldwide. The major active ingredient responsible for the
actions of Panax ginseng is ginsenoside, a four-ring, steroid-like
structure with sugar moieties [6]. Traditional clinical practice
recommends prescriptions containing ginseng in conjunction with
chemotherapy to reduce the side-effects of anti-cancer drugs [7]. A
recent study showed that the acidic polysaccharide of ginseng is a
candidate therapeutic agent with radioprotective activity and
enhances the number of hematopoietic and immune cells (bone
marrow and spleen cells) in irradiated mice [8]. Another study
demonstrated protective effects of total saponins from stem and
leaf of Panax ginseng against cyclophosphamide-induced genotoxi-
city and apoptosis in mouse bone marrow cells and peripheral
lymphocyte cells [9]. Ginsenosides, which generally constitute one
of the major active components of ginseng, are amphiphilic in
nature and display the ability to intercalate into the plasma
membrane. There is evidence to suggest that ginsenosides interact
directly with specific membrane proteins. The ginsenoside, Rg1,
enhances ex vivo bone marrow stromal cell proliferation to a
significant extent in a dose-dependent manner. Since bone
marrow stromal cells (BMSCs) play important roles in hemopoiesis
and regulating immunoreactivity, the ability of Rg1 to enhance
BMSC proliferation is of potential value for clinical applications
[10]. Previous research has additionally shown that Rg1 has
estrogen-like properties and exerts its action via activation of
estrogen receptor alpha in MCF-7 cells [11]. As Rg1 can interact
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promotes the recruitment of immature and mature granulocytes
from the bone marrow reservoir and prolongs the life-span of
mature granulocytes by lowering susceptibility to apoptosis [12].
The mechanism underlying the protective role of Korean
ginseng against 5FU-induced myelotoxicity and identification of
the active component that supports its action during myelopoiesis
remain significant challenges in cancer treatment. In the present
study, we have focused on the immunogenic activity of KG against
5FU-induced myelosuppression in mice and bone marrow cells
cultured in vitro, as well as the role of the predominant component,
ginsenoside Rg1, in myelopoiesis in vitro.
Results
Effects of KG on 5FU-induced hematotoxicity and loss of
body weight
Initially, we examined the protective effects of KG (25, 50 and
100 mg/kg) against the toxic effects of 5FU on white blood cell
(WBC), lymphocyte, neutrophil, platelet, Hb and red blood cell
counts as well as hematocrit levels in the peripheral blood of mice at
different time-points (0, 3, 5, 7, 10 and 14 days). The experimental
designfortheinvitroandinvivostudieswasshowninFig.1A,B,C.
Leucopenia (Fig. 2A), neutropenia (Fig. 2B), lymphocytopenia
(Fig. 2C) and thrombocytopenia (Fig. 2D) were apparent 3 days
after 5FU injection. As shown in Fig. 3A, B, C, peripheral anemia,
erythrocytopenia and decline in the hematocrit level were evident
5 days after a single intraperitoneal dose of 5FU (200 mg/kg).
Recovery of these parameters began after day 11. Significant body
weight loss was observed on days 5, 7 and 10 in mice treated with
5FU (Fig. 3D). A rebound reaction was observed for WBC,
lymphocyte, neutrohil, and platelet counts on day 14 (Fig. 3A).
Mice subsequently treated with KG (50 and 100 mg/kg)
displayed improvements in leucopenia and lymphocytopenia on
days 3, 5, 7 and 10. Treatment with 50 mg/kg KG prevented
early neutropenia, whereas 100 mg/kg KG prevented neutrope-
nia on days 3, 7 and 10. Thrombocytopenia on days 7 and 10 was
improved in mice administered KG (50 and 100 mg/kg),
compared to those treated with 5FU alone. Improvement of
anemia, erythrocytopenia, and decline in hematocrit after KG
treatment were not statistically significant, compared with the
5FU-induced group. The group of mice treated with the lowest
dose of KG (25 mg/kg) displayed improvements in leucopenia and
neutropenia on day 3. The optimal effect of KG on 5FU-induced
hematotoxicity was evident on day 7 after 5FU administration. A
significant decline in body weight was observed on days 7 and 10
in mice treated with the lowest dose of KG (25 mg/kg), but not
those treated with higher doses (50 and 100 mg/kg) of KG. In our
experiments, 200 mg/kg 5FU did not induce lethality, and a
similar hematological pattern was observed in the group of mice
sacrificed on day 7 (data not shown).
Effects of KG on 5FU-induced histopathology of bone
marrow, spleen and thymus
The weights of organs, such as spleen and thymus, were
significantly reduced after 5FU administration. KG (50 mg/kg)
improved spleen weight alone, while KG (100 mg/kg) improved
both spleen and thymus weights (Fig. 4A). The bone marrow
histology results obtained from mice exposed to high doses of 5FU
and KG are shown in Fig. 4B. In contrast to untreated control
mice (Normal), 5FU and KG-treated mice showed bone marrow
cytotoxicity, hypocellularity and appearance of’ adipocytes.
Interestingly, these morphological changes were significant in
5FU-treated mice, while KG (50 and 100 mg/kg)-treated mice
showed moderate hypercellularity and resistance to 5FU-induced
cytotoxicity (Fig. 4B). Spleen tissue histology after 5FU treatment
revealed significant hypocellularity in the white and red pulp
regions and destruction of capsule. These features were distinctly
alleviated after KG treatment, particularly at doses of 50 and
100 mg/kg. Normal thymus is composed of sheets of small and
medium lymphocytes, and exhibits normal cellularity. 5FU
injection into mice resulted in altered thymic architecture
characterized by hypocellularity and loss and pale staining of
lymphocytes. Post-treatment with KG led to moderate protection
against hypocellularity in the cortex and medulla regions.
Effects of KG on 5FU-induced myelopoiesis
To elucidate the specific mechanisms associated with the KG-
induced increase in myelopoiesis genes in vivo, we treated a group
of mice with 5FU, followed by KG. We observed marked
Figure 1. Invivo experimental design (A), C57BL6 (n=40) were treated with 5FU (200 mg/kg, i.p) on day zero and post-treated
(24 h) with KG (25, 50 and 100 mg/kg) for six days, daily once. Complete blood count (CBC) was taken at 0, 3, 5, 7 10 and 14 day. C57BL6
mice (n=40) were treated with 5FU (200 mg/kg, i.p) on day zero and post-treated (24 h) with KG (25, 50 and 100 mg/kg) for six days, sacrificed on
day 7 for cytokines, histopathology, gene expression and colony forming studies (B). Bone marrow cells isolated from C57BL6 were cultured and
treated with KG (0.2, 2, 20 and 200 mg/ml) or Rg1 (0, 0.5, 1 and 1.5 mmol/L) at for cytokines (ELISA) and gene expression by semi quantitative and
quantitative PCR (C).
doi:10.1371/journal.pone.0033733.g001
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spleen tissue (Fig. 5 A, B, C, D). Interestingly, IL-1 mRNA
expression was significantly enhanced in a dose-dependent
manner, following treatment with KG. Similarly, SCF and c-Kit
levels were increased after KG treatment. However, IL-4 mRNA
expression was not significantly increased in the presence of KG.
Effects of KG on 5FU-induced changes in GM-CSF, IL-3
and CFU-GM
Serum levels of IL-3 and GM-CSF were significantly decreased
on day 7 after 5FU injection (Fig. 6A). The group of mice treated
with 100 mg/kg KG showed significant increase in IL-3 and GM-
CSF levels, while changes in the levels of IL-3 and GM-CSF in the
presence of 25 and 50 mg/kg KG did not display statistical
significance, compared to that in mice treated with 5FU alone.
Granulocyte macrophage colony forming unit of bone marrow
cells (CFU-GM) in the group of mice treated with 5FU was
significantly lower (approximately 5-fold), compared with the
normal control group, indicating reduced cellularity (Fig. 6B).
Mice treated with 50 and 100 mg/kg KG displayed bone marrow
reconstitution, as observed from the significant increase in GM
colony forming units (by 3-fold), compared to the group treated
with 5FU alone.
Effects of KG on IL-3 and GM-CSF release in cultured
bone marrow cells
To evaluate whether KG directly affects the bone marrow
environment to accelerate the release of IL-3 and GM colony
stimulation factor (GM-CSF), cultured bone marrow cells were
treated with different doses of KG (Fig. 6 C and D). Compared
with control cells, KG (0.2, 2, 20 and 200 mg/ml) promoted IL-3
release in bone marrow conditioned medium after 24 h of
stimulation. The GM-CSF level was increased significantly after
KG (0.2, 2 and 20 mg/ml) treatment. However, the highest dose of
KG (200 mg/ml) did not induce significant release of GM-CSF,
compared with control (untreated) cells.
Effect of KG on expression of myelopoiesis genes in vitro
We assessed an array of mRNA expression patterns to
determine the effects of KG on cultured bone marrow cells at
two time-points (4 and 8 h). KG treatment for 4 h dramatically
enhanced c-Kit mRNA expression in a dose-dependent manner,
while expression in mice treated with KG for 8 h was similar to
that observed in untreated (normal) and 0.2 or 2 mg/ml KG-
treated groups. Treatment with 20 and 200 mg/ml KG induced a
2-fold increase in the c-Kit mRNA level (Fig. 7a). FasL was
significantly activated after 4 h of treatment with KG (0.2, 2 mg/
ml) (.2-fold) and .3-fold with 20 or 200 mg/ml KG. After 8 h of
Figure 2. Effects of KG on Haematologic parameters in 5FU treated mice. Before and after 24 h of 5FU injection and KG treatment, about
60–100 ml of retro orbital sinus blood was collected using heparin coated capillary tube at different days (0, 3, 5 7 10 and 14) and haematological
parameters such as (A) white blood cells (WBC), (B) neutrophils, (C) lymphocytes (absolute number) and (D) platelets were measured. Data were
expressed as means 6 SD (n=8).
*P,0.05
**P,0.01, normal Vs. 5FU and KG Vs. 5FU.
doi:10.1371/journal.pone.0033733.g002
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relatively smaller degree than untreated control cells (Fig. 7B). IL-1
was activated by 20–60% after 4 h and 8 h treatment with KG
(0.2–200 mg/ml) (Fig. 7C).
We observed no significant upregulation of IL-2 mRNA
expression after 4 and 8 h treatment with KG. Administration
of 200 mg/ml KG enhanced gene expression by 0.5-fold, while
treatment with lower concentrations (0.2 mg/ml) led to extremely
low expression, compared to that in untreated cells (normal)
(Fig. 7D). Similarly, IL-6 gene expression was slightly increased
after 4 h of KG (0.2 and 2 mg/ml) treatment, but remained very
low at 8 h KG treatment at these doses. KG administered at
concentrations of 20 and 200 mg/ml promoted a slight increase in
IL-2 after 8 h of treatment (Fig. 7E). However, we observed
significant activation of IL-12 mRNA (,0.5- to 2-fold, respective-
ly) after 4 h of KG treatment at a range of doses (0.2–200 mg/ml).
KG (0.2 mg/ml) did not significantly promote IL-12 at 8 h, but
enhanced IL-12 expression at doses of 2 and 20 mg/ml (Fig. 8A). A
small increase in MCP1 was observed after 4 h of treatment with
KG (0.2 mg/ml), while a gradual decline was observed at the 2–
200 mg/ml concentration range. After 8 h of treatment with KG
(2 and 20 mg/ml), expression was enhanced by 0.2-fold, compared
to that in control cells (Fig. 8B).
Expression patterns of progenitors, TGF-beta, IFN-gamma and
TNF-alpha, which play a vital role in hematopoietic lineage, were
further examined. After 4 h of treatment, KG (0.2–200 mg/ml)
induced a .0.2-fold increase in TGF-beta expression and at 8 h (2
and 20 mg/ml KG), up to a 0.2-fold increase, compared to
untreated control group (Fig. 8C). After 4 and 8 h of stimulation,
IFN-g gene expression was increased by 60% and 90% in 0.2 and
20 mg/ml KG-treated groups, respectively, and by 40% in the KG
(200 mg/ml) group. At the 8 h time-point, 0.2 and 2 mg/ml KG
induced a 20% increase in IFN-g gene expression, 20 mg/ml KG
led to a 40% decrease and 200 mg/ml KG induced a 50% decline
(Fig. 8D). Similarly, the TNF-alpha level was increased by 10%
after 4 h stimulation with KG 20 mg/ml KG, while the other
doses did not elevate expression. Instead, a 30–40% decline in
expression was observed, compared to untreated cells. At 8 h, KG
(2, 20 and 200 mg/ml) led to a 20–40% increase in TNF-a,
compared to untreated control cells (Fig. 8E).
Effect of Rg1 on myelopoiesis gene expression in vitro
The amounts of protopanaxadiol and protopanaxatriol ginseno-
sides in KG extracts assessed using the high performance liquid
chromatographic system (HPLC) are shown in (Fig. 9A). On the
HPLC profile, Rg1 displayed the highest concentration (mg/kg).
Figure 3. Effects of KG on Haematologic parameters and body weight changes in 5FU treated mice. Before and after 24 h of 5FU
injection and KG treatment, about 60–100 ml of retro orbital sinus blood was collected using heparin coated capillary tube at different days (0, 3, 5 7
10 and 14) parameters such as (A) hemoglobin, (B) red blood cells (RBC), (C) hematocrit and (D) body weight were measured. Data were expressed as
means 6 SD (n=8).
*P,0.05
**P,0.01, normal Vs. 5FU and KG Vs. 5FU.
doi:10.1371/journal.pone.0033733.g003
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in promoting the immunogenic role of KG. Accordingly, the
mRNA expression patterns of c-kit, IL-6 and TNF-a in cultured
bone marrow cells were examined at the two time-points of 4 and
8 h. Treatment with Rg1 did not affect c-Kit mRNA expression at
the 4 h time-point while 1.5 mMol Rg1 induced a significant
decline (Fig. 9B). IL-6 was significantly decreased after 4 h of KG
(0.5, 1.5 mg/ml) and 8 h of Rg1 (1, 1.5 mMol) treatment (Fig. 9C).
TNF-a was activated by 40–60% after 4 h and 70–120% after 8 h
of exposure to Rg1 (Fig. 9D).
Discussion
Hematological cytopenia resulting from chemotherapy is one of
the major dose-limiting factors of cancer treatment. Attempts to
reduce cytopenia, for instance, with the use of hematopoietic
factors may lead to escalation of the cytotoxic dose for effective
destruction of cancer cells. A commonly accepted theory is that
several hematopoietic factors have the potency to shorten
cytopenic intervals when administered to chemotherapy patients.
Consequently, the doses of chemotherapy drugs, such as 5FU,
have been increased in a number of trials to accelerate effects.
However, while cell proliferation is slowly decreased, the anti-
cancer effect is not significantly enhanced at high doses of 5FU
[13]. Therefore, to alleviate bone marrow suppression by 5FU,
natural products like ginseng are preferred for promoting
hematopoiesis, proliferation and differentiation of myeloid pro-
genitor cells. Our hematologic results showed that intraperitoneal
injection of 5FU dramatically affects blood parameters, signifying
severe cytopenia in mice. As neutrophil, leukocytes have the
shortest half-life in circulation, their continuous renewal is essential
to prevent the sequel of chemotherapeutic agent-induced neutro-
penia, leucopenia, and thrombocytopenia. These effects were not
completely alleviated, but critical loss of total white blood cells,
lymphocytes, neutrophil and platelets was significantly attenuated
after treatment with KG at doses of 50 and 100 mg/kg. This
accelerated hematopoietic restoration after injury indicates that
KG plays a role in enhancing the proliferation of myeloid
progenitors. Earlier reports have demonstrated that cyclophos-
phamide-induced leucopenia is effectively alleviated by the
ginsenoside, Rg1 [9]. Consistent with peripheral blood analysis
data, injection of 5FU induced a drastic reduction in the cellular
Figure 4. Effects of KG on Organ weight and Histopathology. After 24 h of 5FU injection and 6 days of KG treatment, group of mice were
sacrificed under ether anesthesia on day 7 and organ weights such as spleen and thymus were measured using an automated electronic balance (A)
Organs such as spleen, thymus and bone marrow were removed and processed for Haematoxylin and Eosin (B). The stained tissues were examined
under a light microscope (200X magnifications). Data were expressed as means 6 SD.
*P,0.05
**P,0.01, a – normal Vs. 5FU, b – KG Vs. 5FU.
doi:10.1371/journal.pone.0033733.g004
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tion and increased bone marrow cellularity were improved
following KG treatment. Spleen cell damage was considerably
improved after KG treatment, while recovery of thymus damage
was not significant. These cumulative effects support an anti-
cytotoxic effect of KG, as well as a positive role in hematopoietic
lineage development.
Interleukin 1, a major cytokine, induces proliferation and
differentiation of lymphocytes and neutrophil activation. IL-1 is
one of the important primary factors in the biological defense
mechanism that enhances the restoration of stem and progenitor
subpopulations in murine marrow, accelerating hematopoietic
recovery in chemotherapy induced myelosuppressed mice [14].
Similarly, SCF and CD-117 (c-Kit) are well-known major
hematopoietic stimulators in chemotherapy or radiation-induced
myelosuppression. A recent study showed that SCF, the ligand for
the c-kit tyrosine kinase receptor, plays an important role in
megakaryopoiesis and interacts with many other cytokines to
promote myeloerythroid and lymphoid stem cells [15,16]. In view
of the significant elevation of serum IL-3 and GM-CSF after KG
treatment, it is reasonably hypothesized that activation of SCF and
its receptor stimulates proliferation and maturation of granulocytes
andmacrophagemyeloidcells.Thiscytokineadditionallystimulates
various functions of leukocytes, including cytotoxicity of granulo-
cytes and macrophages, phagocytic activity, and degranulation of
neutrophils. IL-3 accelerates the recovery of circulating hemato-
poietic lineage suppressed byspecific chemotherapy agents and acts
as an early differentiator of stem cells [17]. This cytokine
additionally stimulates the growth and effector functions of mature
cells, such as macrophages and lymphocytes [18]. IL-3 and GM-
CSF levels are drastically low in sera of mice injected with 5FU,
indicative of a defect in the hematopoietic lineage during
hematopoiesis. The observed improvements after treatment with
KG (100 mg/kg) support itsroleinmodulating earlyhematopoietic
factors against 5FU-induced myelosuppression.
The CFU-GM content was suppressed 2-fold in 5FU-damaged
bone marrow in mice compared to their untreated counterparts.
KG enhanced the CFU-GM level by 3.5-fold, compared to that in
mice treated with 5FU alone, indicating amelioration of side-
effects, such as stimulates the differentiation and proliferation of
granulocytes and monocytes in myeloid lineage progenitor cells.
Earlier reports have demonstrated that Panax notoginosides or
Figure 5. Effects of KG on 5FU-induced changes gene expression in spleen. Total RNA was extracted from the spleen cells, mRNA of (A) IL-1,
(B) SCF, (C) c-Kit and (D) IL-4 were analyzed by semi quantitative PCR using specific forward and reverse primers. Data (means 6 SD). *p,0.05, Normal
Vs. 5FU and KG Vs. 5FU.
doi:10.1371/journal.pone.0033733.g005
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blood cells, improves the hematopoiesis function of bone marrow,
and promotes the proliferation of hematopoietic CFU-GM and
CFU-E progenitors in mice with immune-mediated aplastic
anemia upon bone marrow suppression [19]. The interrelation-
ship between human health and herbal medicines is well
documented. The bioactive constituents of Panax ginseng are
believed to be saponins, and their unique chemical compositions
are related to various pharmacological effects, including anti-
cancer, anti-inflammatory, radioprotection, anti-emesis, immune
stimulating, and anti-aging acitivites [20]. HPLC analysis has
revealed the presence of high amounts of Rg1, Rb3, and Rb1 in
KG. Moreover, recent studies have shown that the ginsenoside,
Rg1, a steroidal saponin abundant in ginseng, is one of the most
active components responsible for many of its pharmacological
effects. Consistently, another study has reported that the ginseno-
side, Rg3, exerts a hematopoietic effect by enhancing the
proliferation of bone marrow cells and splenocytes [20,21]. In
the present investigation, we have employed a saponin-rich
fraction of KG. However, the specific agent responsible for
augmentation of hematopoietic stimulators is yet to be clarified.
To determine the direct effect of KG on myelopoiesis we
monitored the levels of IL-3 and GM-CSF in cultured bone
marrow cells treated with KG. The utility of IL-3 with the GM-
CSF protocol has been confirmed by a number of in vitro and in vivo
studies. Both IL-3 and GM-CSF have pleiotropic effects on
hematopoietic cells and exhibit overlapping activities [22].
However, IL-3 targets the earliest progenitors to induce their
proliferation, differentiation, survival, and progeny, while GM-
CSF is a hematopoietic cytokine with the ability to stimulate
proliferation and maturation of granulocyte and macrophage
myeloid cells [23]. The results from these analyses suggest a role of
KG in enhancing the production of hematopoietic factors and
proliferation of hematopoietic progenitor cells for the recovery of
mice from 5FU-induced leucopenia or improved cytokine release
indicates that KG enhances cytokine production by lymphocytes.
One report suggested that total saponin of panax ginseng promotes
hematopoietic factors and induces endothelial cells and monocytes
in the microenvironment to synthesize and secrete GM-CSF,
either through a direct or indirect route [24]. Consistently, reports
have shown that Panax notoginosides acts as a growth factor or
displays synergistic efficacy with other growth factors (such as stem
Figure 6. Effects of KG on 5FU induced changes IL-3, GM-CSF and CFU-GM. Serum separated from blood collected from abdominal aorta of
mice was subjected to cytokine analysis using Elisa kit (A). Bone marrow cells isolated from mice were grown in MethoCult methylcellulose-based
complete medium in a 5% CO2 incubator for 14 d (B). Isolated bone marrow cells cultured in 6 well plated treated with KG (0.2, 2, 20 200 mg/ml) for
24 h and conditioned media was subjected to cytokine (pg/ml) analysis using commercial kit method (C &D). Data were expressed as means 6 SD.
*P,0.05
**P,0.01 compared with normal, a – normal Vs. 5FU, b – KG Vs. 5FU.
doi:10.1371/journal.pone.0033733.g006
Panax ginseng and Rg1 on Myelopoiesis
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e33733cell factor, GM-CSF and IL-3) in the proliferation of hematopoi-
etic stem/progenitor cells [25,26].
In recent decades, the discovery of new natural noble agents has
been extensively pursued, with a view to reducing the deleterious
side effects of chemotherapy. Recombinant cytokines are well-
characterized as immune modulators [27–29] and have been
applied in immunotherapy for a variety of cancers. However, these
compounds tend to be too toxic with very short half-lives,
suggesting that their endogenous induction is a more effective
immunotherapeutic approach in cancer treatment and improving
Figure 7. Effects of KG on genes c-Kit, FasL, IL-1, IL-2 and IL-6 in bone marrow cells. Bone marrow cells treated with KG (0.2, 2 20 and
200 mg/ml) for 4 and 8 h (n=3). Total RNA was isolated from bone marrow cells using RNAase mini kit and analyzed by semi quantitative PCR using
mouse specific primers. The relative intensities of the bands (F) were determined with the use of the ratios to b actin (normalized) and expressed as
percentage (A–E).
doi:10.1371/journal.pone.0033733.g007
Figure 8. Effects of KG on genes IL-12, MCP1, TGF-b, IFN-c and TNF-a in bone marrow cells. Bone marrow cells treated with KG (0.2, 2 20
and 200 mg/ml) for 4 and 8 h (n=3). Total RNA was isolated from bone marrow cells using RNAase mini kit and analyzed by semi quantitative PCR
using mouse specific primers. The intensities of the bands (F) were determined with the use of the ratios to b actin (normalized) and expressed as
percentage (A–E).
doi:10.1371/journal.pone.0033733.g008
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mechanism underlying the anti-myelosuppression activity of KG,
we analyzed the relevant myelopoiesis-promoting factors in
cultured bone marrow cells. Factors, such as c-kit, FasL, IL-1,
IL-2, and IL-6, are involved in various stages of development of
granulocyte-monocyte/macrophage lineage and hematopoietic
stimulators [31]. The ability of SCF to protect megakaryocytic
progenitors from chemotherapy-induced myelosuppression signi-
fies a link between c-kit signaling and thrombocytopenia that may
influence the extent of megakaryocyte loss during chemotherapy.
Several pharmacologic agents that inhibit c-kit frequently induce
megakaryocyte loss and thrombocytopenia. Thrombocytopenia is
particularly evident when 5FU is combined with other chemo-
therapeutic drugs, suggesting that interactions between c-kit and
endogenously produced SCF are important for megakaryocyte
survival in myelosuppressive conditions. IL-1 affects hematopoiesis
via different mechanisms [32]. The enhanced c-kit and IL-1
expression in bone marrow cells suggests that KG is more effective
if administered simultaneously with chemotherapeutic treatment
and during the entire duration of the chemotherapy cycle to
prevent the occurrence of drug-induced myelosuppression.
However, cultured bone marrow cells treated with Rg1 alone
did not enhance c-kit expression. Ginsenosides present in the KG
may have diverse as well as synergistic actions, and therefore the
possibility of other active principles in KG extracts contributing to
immunogenic activity cannot be ruled out at this stage.
Interleukin 6 (IL-6) is a cytokine produced by a number of
normal and transformed cell lines [33]. IL-6 can either promote or
inhibit the growth of tumor cells, depending on the cell type. IL-6
acts in concert with IL-3 to induce multilineage progenitors from
murine spleens and M-CSF to stimulate the number and size of
CFU-M [34]. In our experiments, no significant activation of IL-6
was observed following 4 h and 8 h treatment with KG or Rg1, in
contrast to earlier reports demonstrating that ginsan elevates IL-6
mRNA expression in animal models [35,36]. Hematopoiesis is a
diverse process regulated by various hematopoietic growth factors.
In addition to IL-6, other factors, such as IL-1, GM-CSF, IL-3 and
stem cell factor, may act on early hematopoietic lineages.
Figure 9. Compositional analysis of KG and role of Ginsinoside Rg1 on IL-6, c-Kit and TNF-a in bone marrow cells. Column was eluted
with solvents A (18% Acetonitrite) and B (80% Acetonitrite) at flow rate of 2.5 ml/min. Solution 100% A and 0% B changing over 32 min, 80% A and
20% B to 80 min, 0% A and 100% B to 100 min, and 100% A and 0% B to 110 min were used, amount of ginsinosides present (n=3) were expressed
in mg/kg (A). (b–d) Bone marrow cultured cells were treated with Ginsinoside Rg1 (0.5, 1 and 1.5 mmol/L) for 4 and 8 h. mRNA isolated from bone
marrow cells using Trireagent and products were analyzed by quantitative PCR using specific primers. Results were normalized by using the reference
gene, actin, and are represented as percentage versus the reference gene. Data were expressed as means 6 SD.
*p,0.05,
**p,0.01 compared with 4
h blank control (Untreated),
#p,0.05,
##p,0.01 compared with 8 h blank.
doi:10.1371/journal.pone.0033733.g009
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association of KG with protection against myelotoxicity or
hematopoiesis [37].
IL-2 was primarily explained as a mitogenic signal and growth
factor for T lymphocytes [38]. The findings of differential
expression of IL-2R during in vitro differentiation of human
myeloid cells and increase in the number of colony-forming unit-
granulocyte/macrophage (CFU-GM) progenitor cells after treat-
ment of cancer patients with IL-2 are consistent with its positive
effect on myelopoiesis. However, other studies have reported
contradictory findings [39]. In the absence of IL-2, mice develop a
profound hematopoietic disorder characterized by defective
myelopoiesis and decreased number of mature granulocytes. We
obtained conflicting data on IL-2 expression in our experiments
[40]. Low concentrations of KG did not enhance IL-2 gene
expression, while the highest dose induced a considerable increase
in expression. A dose of 20 mg/ml KG-induced slight activation
following 8 h of treatment, but not the other concentrations.
Considering the link between CFU-GM and IL-2, we examined
the effect of KG on CFU-GM expression. No inhibition of the
CFU-GM level was evident. Although serum IL-2 was not
monitored, we propose that depending on the cell type, KG
promotes myelopoiesis without affecting colony forming units.
However, further experiments are necessary to clarify its
mechanism of action.
Fas and FasL influence human hemopoietic progenitor cell
numbers in different in vitro systems [41]. Until recently, studies on
the involvement of Fas and FasL in hemopoiesis have focused on
their proapoptotic functions. However a number of reports
indicate that activated downstream caspases can exert regulatory
effects in the absence of cell death. Fas, FasL, and caspase
activation are likely to play an important role in the regulation of
myelopoiesis [42]. FasL was significantly elevated after 4 and 8 h
treatment with KG, this observation leads to a hypothetical
hypothesis that regulation of myelopoiesis may be via non-
apoptotic pathway. Earlier reports have shown that panax
notoginseng not only stimulates cell proliferation but also inhibits
the activity of caspases and apoptosis of hematopoietic cells [9,26].
Specific cytokines, including IL-1 and IL-12, stimulate the
precursors of bone marrow cells and display radioprotective and
chemoprotective activities [43,44]. Our results clearly showed that
KG increases IL-12 expression. It is believed that the chemopro-
tective effects of KG on bone marrow cells are mediated through
IL-12. Consistently, a recent report showed enhancement of IL-12
expression by the acidic polysaccharide of ginseng. Enhancement
of IL-12 within the tumor environment has been shown to
contribute to tumor clearance through a variety of mechanisms,
including restoration of the cytotoxicity of tumor-resident CD8+
T-cells [8]. Therefore, IL-12 activation after KG treatment may
play a positive role in cancer treatment strategies, particularly
chemotherapy. MCP1 represents a family of cytokines that were
originally designated on the basis of their activity as chemo-
attractant cytokines for mature blood cells. MCP1s have been
implicated in the control of myelopoiesis, especially as negative
regulators [45]. In our experiments, 4 h treatment with KG
decreased MCP1 expression, while a small increase was evident
upon 8 h treatment. Ginseng exerts a significant inhibitory activity
on MCP1, leading to reduced leukocyte infiltration and inflam-
matory response. Elevated levels of MCP1 following 8 h of KG
treatment may correlate with the earlier report that endogenous
chemokines cooperating with other growth factors inhibit cycling
of primitive normal progenitors in long-term culture. However, its
precise role is yet to be established.
There are no documented studies on the effects of KG on
specific hematopoietic inhibitors, such as TGF-b and IFN-c, in the
literature. Activation of certain inhibitors correlates with hypoth-
esize that some cytokines may accelerate the haematopoietic
development, and the inhibitors like IFN-c, TNF-alpha may keep
the haematopoietic stem cell in a quiescent state to protect them
from exhaustion or from the cytotoxic effect of chemotherapy
drugs [46]. Generally, endothelial cells elaborate TGF-b, which
consequently has an inhibitory effect on progenitor growth.
However, research has shown that TGF not only activates
CD34 antigen before S phase entry but also maintains a high
level of CD34 expression on cells that have escaped cell cycle
inhibition. These lines of evidence suggest that TGF acts as a vital
physiological factor ensuring the maintenance of a stem cell
reserve [47,48]. However, neither of these cytokines was found to
be solely responsible for the inhibitory effect on GM-CFC growth;
rather, the effect was partly caused by synergism between the two
factors, and most likely by other factor(s) that are yet to be
identified [46]. While our experiments showed that TGF-b is
significantly activated upon KG treatment, the precise mechanism
underlying this activation is yet to be established.
Hematosuppression, one of the most severe side-effects of
chemotherapy, may lead to immunological inadequacy, severe
infection, discontinuation of treatment, or even death. There is
evidence to support beneficial roles of IFN-c and GM-CSF in
protective immunity against infection [49]. From this viewpoint,
IFN-c may play a positive role in cancer patients who often
encounter opportunistic infections. However, there have been
conflicting reports on the positive of IFN-c regulatory effect on
myelopoiesis. Ginsenosides, such as Rg3 and Rh2, have been
shown to promote anti-cancer effects and reduce side-effects
during chemotherapy with cyclophosamide [50–52].
TNF is a potent inhibitor of erythropoiesis that suppresses the
growth of erythroid and myeloid progenitors in vitro. These
cytokines, in turn, affect the differentiation of early bone marrow
progenitor cells by altering their response to CSFs [53]. However,
earlier report has shown that TNF-alpha is an important mediator
of the granulocyte-macrophage mature cell lineage, which
increases their phagocytic, cytotoxic, and bacteriocidic properties
[54]. Moreover, TNF-alpha accelerates the release of granulocytes
from bone marrow. The role of TNF-alpha in regulation of
myelopoiesis has been not extensively elucidated [55].
An earlier report demonstrated that ginsan stimulates the
expression of TNF-a and major histocompatibility complex
(MHC) class II molecules in murine dendritic cells and
proliferation of allogeneic CD4 (+) T lymphocytes [8]. Our results
showed that KG modulates TNF-a expression. Specifically, 4 h of
KG treatment has a suppressive effect, while 8 h treatment leads
to significant activation. Recent reports have additionally shown
that Fas expression on hematopoietic progenitor cells is induced by
cytokines, such as IFN-c and TNF-a [41]. These results favor the
hypothesis that KG or Rg1 also stimulates macrophages to
produce cytokines (IL-1, TNF-alpha), which may, in turn, induce
the release of growth factor through lymphocytes, several tissues
and organs, including cells of the bone marrow microenvironment
[56].
The data collectively indicate that KG improves bone marrow
cellular toxicity in 5FU-induced mice and in vitro myelopoiesis, and
accelerates hematopoietic recovery by modulating the release of
cytokines. The ginsinoside, Rg1, a major constituent of KG,
directs the immunogenic property of Korean ginseng to some
extent.
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Preparation of KG and HPLC analysis
Korean P. ginseng root was obtained from Ginseng Nonghyup
(Keum-san, Korea). Sliced ginseng roots (1.2 kg) were boiled in 6.5
l of water for 100 min at 120
uC using a high-speed automatic non-
pressure earthen pot (Kyung-Hee Co-operation, Seoul, Korea),
and the extraction procedure repeated with 4.5 l of water. Then,
KG was centrifuged for 30 min at 1,500 rpm, and the supernatant
lyophilized using a vacuum-freeze drying system and stored at –
40uC. Limulus amebocyte lysate (LAL) assay was performed to
confirm endotoxin levels. The amount of protopanaxadiol and
protopanaxatriol ginsenosides in KG was estimated using High
performance liquid chromatographic system (HPLC). The HPLC
system consisted of a Waters Alliance 2695 HPLC pump, Waters
Alliance 2695 Auto sampler, and Waters 996 PDA (United States,
Connecticut). HPLC conditions were according to a previously
described method (Raghavendran et al., 2010). GinsenosideRg1-
was purchased from Wako Pure Chemical (Osaka, Japan) with
98% HPLC purity.
Animals
Male C57BL/6, (Orientbio, Gyeonggido, Korea) weighing
between 18620 g were used in this study. Mice were housed in
standard polypropylene transparent cages under environmentally
controlled conditions (Temperature, 2262uC; Humidity, 55–60
%) with a 12 h light: 12 h dark cycle (light on 09:00 and 21:00 h).
Mice were fed commercial standard chow (Samtako, Osan, Korea)
and tap water ad libitum. 5FU-induced myelotoxicity experiments
were designed and performed in strict accordance with the
regulations for laboratory animal care (NIH publication No. 85-
23, revised 1985), approved by the Institutional Animal Care and
Use Committee of Daejeon University (DJUARB 2010–017).
Experimental design
After one week acclimatization all mice were randomly divided
into normal (n=13), 5FU (200 mg/kg) alone (n=13), and KG
(25, 50 and 100 mg/kg, orally) treatment (n=13/each dose).
Except normal all the other groups were given 5FU as
intraperitoneal injection on 0
th day and after 24 h, 39 mice were
post treated with KG for 6 consecutive days. For hematology 8
mice from each group were used to check the optimal effect of KG
and 5 animals were sacrificed on day 7 for histopathology,
cytokines and gene expression studies, for colony forming assay
(n=3 mice/group) were used (Fig. 1).
Hematology
Peripheral blood was collected from the retro-orbital venous
plexus with an EDTA-coated capillary tube at different time points
(0, 3, 5, 7, 10 and 14 Days). The red blood cells (RBC),
hemoglobin (Hb), white blood cells (WBC), lymphocytes and
neutrophils, hematocrit (HCT), platelets in each sample were
measured by a HEMA VET 850 automatic analyser (CDC
Technologies, CT, USA).
On the experimental day (7
th) animals were sacrificed under
ether anesthesia and blood was collected from the abdominal
aorta. A portion of the blood was used for red blood cells (RBC),
hemoglobin (Hb), hematocrit (HCT), platelets, white blood cells
(WBC), lymphocytes and neutrophils estimation using an HEMA
VET 850 automatic analyser (CDC Technologies, CT, USA).
Another portion of the blood was subjected to serum separation
and stored at –70uC for cytokine analysis.
Measurement of cytokine levels and histopathological
analysis
Enzyme-linked immuno-sorbent assay (ELISA) kits were
purchased from BD Biosciences (San Diego CA, USA) for assay
of cytokines. The concentrations of IL-3 and GM-CSF in serum
(7
th day) were examined. A standard curve was run on each assay
plate using recombinants of the respective cytokines in serial
dilutions.
Spleen, thymus and right femur from all mice were fixed in 10%
buffered formalin, and the femur was decalcified with Calci-Clear
Rapid (National Diagnostics, Atlanta, GA, USA). Spleen, thymus
and femur were then embedded in paraffin, sectioned at 4 mm,
and stained with hematoxylin-eosin. Representative microphoto-
graphs were obtained with a light microscope (Leica, Wetzlar,
Germany).
Table 1. Primers used for semi-quantitative PCR.
Genes Forward primer Reverse primer
Product size
(bp)
C-Kit, GAACAGGACCTCGGCTAACA GCCATTTATGAGCCTGTCGT 220
FasL, ACTCCGTGAGTTCACCAACC CAAGACTGACCCCGGAAGTA 267
IL-1, AAG CTC TCC ACC TCA ATG GA TGC TTG AGA GGT GCT GAT GT 302
IL-2, TGC TCC TTG TCA ACA GCG TCA TCA TCG AAT TGG CACTC 391
IL-6, TGTGCAATGGCAATTCTGAT TGGTCCTTAGCCACTCCTTC 357
IL-12, ATGTGGGAGCTGGAGAAAGA TGGCCAGCATCTAGAAACTCT 194
MCP1, ATGCAGGTCCCTGTCATG GCTTGAGGTGGTTGTGGA 479
TGF-beta, TGAGTGGCTGTCTTTTGACG TTCTCTGTGGAGCTGAAGCA 310
IFN-g GGA TAT CTG GAG GAA CTG GC GAG CTC ATT GAA TGC TTG GC 250
TNF-a CTCCCAGGTTCTCTTCAAGG TGGAAGACTCCTCCCAGGTA 195
SCF CCTCTTGTCAAAACCAAGGAG GGCCTCTTCGGAGATTCTTT 329
IL-4 TCAACCCCCAGCTAGTTGTC GCATGGAGTTTTCCCATGTT 254
bactin GTG GGG CGC CCC AGG CAC CA CTC CTT AAT GTC ACG CAC GAT TTC 539
doi:10.1371/journal.pone.0033733.t001
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The spleen tissues (100 mg) were homogenized with RIPA
buffer and centrifuged at 10,0006g for 15 min at 4uC. The
supernatant fraction was used for total RNAs extraction using
RNAase midi kit (Qiagen, Valencia, CA, USA). Sixteen
microliters of double distilled water mixed with 1 ml of forward
and reverse primers and mixture was added to PCR pre mix
(Bioneer, Korea). Then 3 ml of cDNA was added to each tube.
PCR amplification was carried out using a protocol initial
denaturation temperature of 94 degree for 10 minutes followed
by 30 cycle’s amplification at (94 degree 1 min, 60 degree 40 s,
72 degree 40 s). with an additional extension at 72uC for 10 min.
The PCR products were fractionated on a 1% agarose gel and
visualized by ethidium bromide staining. The band intensity of
ethidium bromide fluorescence was measured using NIH Image
Analysis Software Version 1.61 (National Institutes of Health,
Bethesda, MD). The nucleotide sequences of forward and reverse
primers used for PCR are shown in Table 1.
Isolation of bone marrow cells
Bone marrow stem cells were harvested from the femurs of
C57BL/6 male mice. Bones were briefly immersed in 70% ethanol
(3 s), and rinsed four times (2 minutes each) in Phosphate Buffer
Solution containing antibiotics (penicillin-streptomycin) under
sterile conditions. The epiphyses of each bone were removed with
a razor blade, and the marrow was flushed from the diaphysis with
a syringe and 26.5-gauge needle and collected in DMEM
(Welgene, Daegu, Korea) containing 10% (v/v) fetal bovine serum
(FBS, Welgene) and 1% penicillin-streptomycin mixture (Wel-
gene). The marrow cell suspension was gently drawn through an
18-gauge needle to mechanically dissociate the mixture into a
uniform single cell suspension. Nucleated cells were counted using
a blood cell counter (HEMAVET; CDC Technologies)
Colony-forming and cytokine assay
To examine the effects of KG on bone marrow stem cells,
C57BL/6 mice were injected intraperitoneally with 5FU (0.2 g/
kg). Mice were given KG (25, 50 and 100 mg/kg) or distilled water
(for naive and control groups) for 6 consecutive days after the
0
th day of 5FU injection. After thoroughly mixing the nucleated
cells (1610
5) with 4 mL MethoCult methylcellulose-based com-
plete medium (Stem Cell Technologies, Seattle, WA, USA), media
(1.1 mL per dish in triplicate) were cultured in a 5% CO2
incubator for 14 d. According to the morphological characteris-
tics, the number of colonies assessed by CFU-GM was counted
under an inverted microscope.
Bone marrow cells isolated from C57BL/6 male mice were
seeded in a six-well culture plate (1610
5 cells per well), and treated
with or without KG, Normal (untreated control cells) 0.2, 2, 20
and 200 mg/ml in a 5% CO2 incubator. After 24 h of incubation
with KG, conditioned medium of bone marrow cells were
collected and subjected to cytokine analysis (IL-3 and GM-CSF)
using BD Biosciences (San Diego CA, USA) for assay of cytokines.
A standard curve was run on each assay plate using recombinants
of the respective cytokines in serial dilutions.
Semi quantitative and Quantitative PCR
Bone marrow cells were seeded in a six-well culture plate
(5610
6 cells per well), and treated with or without KG Normal
(untreated control cells), 0.2, 2, 20 and 200 mg/ml) for two points 4
and 8 h. After purification of total RNA using an RNAase mini kit
(Qiagen, Valencia, CA, USA). To determine the expression
pattern of all mRNA, 1 mL of cDNA was amplified by a thermal
cycler (TaKaRa, Japan) using the specific primers. The PCR
mixture was made as follows; 1.5 U of Taq DNA polymerase
(Bioneer, Korea), 3 mL of dNTPs 10 mmol/L, 3 mLo f1 0 6PCR
buffer, 1 mL of 10 pmol forward and reverse primers, and 1 mLo f
cDNA in 19.7 mL of ultra distilled water. PCR amplification was
carried out using a protocol of initial denaturing step at 95uC for
10 min, then 32 cycles of amplification (at 95uC for 1 min, at 60uC
for 40 s, and at 72uC for 40 s ), and additional extension at 72uC
for 10 min. The PCR products were fractionated on a 1% agarose
gel and visualized by ethidium bromide staining. The band
intensity of ethidium bromide fluorescence was measured using
NIH Image Analysis Software Version 1.61 (National Institutes of
Health, Bethesda, MD). The intensities of the bands were
determined with the use of the ratios to b actin (normalized) and
expressed as percentage. The nucleotide sequences of forward and
reverse primers used for PCR are shown in Table 1.
Isolated bone marrow stem cells were plated at 5610
6 cells/well
in 6-well plate for overnight, and treated with 0.5,1.5 mM
concentrations of Rg1 for 4 h, 8 h, and Normal (untreated control
cells) for 24 h respectively. The levels of mRNA of C-kit, IL-6 and
TNF-a, were determined by quantitative real-time RT-PCR.
Briefly, total RNA was extracted from BMSCs using TriReagent
(Molecular Research Center, Cincinnati, OH). The cDNAs were
then synthesized using 2 mg of RNA template in a 20 ml reaction
using the High-Capacity cDNA Reverse Transcription Kit
(Ambion, Austin, TX). PCR amplifications were quantified using
the SYBRGreen supermix reagent (Bio-Rad, CA) according to the
manufacturer’s protocol. All primer (Table 2) sets produced
amplicons of the expected size, and their identities were also
verified by sequencing. The cycling conditions were 95uC for
10 min, followed by 40 cycles of 95uC for 10 s, 60uC for 20 s, and
72uC for 33 s. To detect and eliminate possible primer-dimer
artifacts, a dissociation curve was generated by adding a cycle of
95uC for 15 s, 60uC for 1 min, and 95uC for 15 s. Results were
normalized by using the reference gene, actin, and are represented
as percentage versus the reference gene Table 2.
Statistical analysis
Data analysis was performed using the Statistical Package for
Social Science (SPSS for Windows, version 10.0, 1999, SPSS Inc,
Chicago, USA). Data are expressed as means 6 SD. We used one-
way ANOVA followed by Least Significance Deviation method
and the differences were considered significant if P,0.05 P,0.01
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Table 2. Primers used for quantitative RT-PCR.
Genes Forward (59-39) Reverse (59-39)
Actin ACCGTGAAAAGATGACCCAG TCTCAGCTGTGGTGGTGAAG
c-kit TGTGTCTACATCCGTGAACTCCAT AGCGTCTCCTGGCGTTCATA
IL-6 GACTTCCATCCAGTTGCCTTCTT TCCACGATTTCCCAGAGAACA
TNF-a CGTCGTAGCAAACCACCAAGT TTGAAGAGAACCTGGGAGTAGACA
doi:10.1371/journal.pone.0033733.t002
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